The Medicines Optimisation Innovation Centre: a dedicated centre driving innovation in medicines optimisation-impact and sustainability

Author:

Hogg A.ORCID,Scott M.ORCID,Fleming G.ORCID,Scullin C.ORCID,Huey R.ORCID,Martin S.ORCID,Goodfellow N.ORCID,Harrison C.

Abstract

Abstract Background Sub-optimal medicines use is a challenge globally, contributing to poorer health outcomes, inefficiencies and waste. The Medicines Optimisation Innovation Centre (MOIC) was established in Northern Ireland by the Department of Health (DH) in 2015 to support implementation of the Medicines Optimisation Quality Framework. Aim To demonstrate how MOIC informs policy and provides support to commissioners to improve population health and wellbeing. Setting MOIC is a regional centre with multidisciplinary and multi-sector clinical expertise across Health and Social Care and patient representation. Development Core funded by DH, MOIC has a robust governance structure and oversight programme board. An annual business plan is agreed with DH. Rigorous processes have been developed for project adoption and working collaboratively with industry. Implementation MOIC has established partnerships with academia, industry, healthcare and representative organisations across Europe, participating in research and development projects and testing integrated technology solutions. A hosting programme has been established and evaluation and dissemination strategies have been developed. Evaluation MOIC has established numerous agreements, partnered in three large EU projects and strengthened networks globally with extensive publications and conference presentations. Informing pathway redesign, sustainability and COVID response, MOIC has also assisted in the development of clinical pharmacy services and antimicrobial stewardship in Europe and Africa. Northern Ireland has been recognised as a 4-star European Active and Healthy Ageing Reference Site and the Integrated Medicines Management model as an example of best practice in Central and Eastern Europe. Conclusion MOIC has demonstrated considerable success and sustainability and is applicable to health systems globally.

Publisher

Springer Science and Business Media LLC

Reference68 articles.

1. Donaldson L, Kelley E, Dhingra-Kumar N, et al. Medication Without Harm: WHO’s Third Global Patient Safety Challenge. Lancet. 2017;389(10080):1680–1.

2. Naseralallah L, Stewart D, Price M, et al. Prevalence, contributing factors, and interventions to reduce medication errors in outpatient and ambulatory settings: a systematic review. Int J Clin Pharm. 2023;45(6):1359–77.

3. World Health Organization. Global burden of preventable medication-related harm in health care: a systematic review. 2023. ISBN:978-92-4-008888-7. https://www.who.int/publications/i/item/9789240088887. Accessed 21 May 2024.

4. The European Commission. A European One Health Action Plan against Antimicrobial Resistance (AMR). 2017. https://health.ec.europa.eu/system/files/2020-01/amr_2017_action-plan_0.pdf. Accessed 21 May 2024.

5. Saeed D, Carter G, Parsons C. Interventions to improve medicines optimisation in frail older patients in secondary and acute care settings: a systematic review of randomised controlled trials and non-randomised studies. Int J Clin Pharm. 2022;44(1):15–26.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3